SI

SIGA Technologies, Inc.

SIGAHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$94.6M
-31.8% YoY
Net Income
$23.3M
-60.7% YoY
EBITDA
$24.3M
-65.6% YoY
Free Cash Flow
-$24.0M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 19CONFIRMED MACD Positive CrossoverHistogram +0.0129, positive momentum
RSI OversoldRSI 28.9, below 30, stock may be oversold
Aug 18CONFIRMED MACD Positive CrossoverHistogram +0.0048, positive momentum
RSI OversoldRSI 23.4, below 30, stock may be oversold
About SIGA Technologies, Inc.

Part of the healthcare sector, SIGA Technologies, Inc. (SIGA) is listed under Drug Manufacturers - Specialty & Generic. Valued at $236.4M, SIGA is a micro-cap name in its sector. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.

Where SIGA stands vs its 150-day and 200-day moving averages

As of the August 19, 2026 close, SIGA finished 34.43% below its 150-day moving average ($4.56) and 38.35% below its 200-day moving average ($4.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is SIGA overbought or oversold?

At the August 19, 2026 close, SIGA's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$236.4M
Fwd P/E3.05
EPS$-0.04
Beta0.89
52W Change-62.4%
ROE-1.5%
Analysis

SIGA Technologies, Inc. holds $117.6M in cash against $439K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$24.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -1.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $110.8M (2022) to $94.6M (2025), a 15% decline worth watching.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for SIGA Technologies, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms